USA - NASDAQ:QTRX - US74766Q1013 - Common Stock
The current stock price of QTRX is 5.505 USD. In the past month the price increased by 13.65%. In the past year, price decreased by -61.62%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 22.05 | 182.23B | ||
DHR | DANAHER CORP | 25.72 | 138.68B | ||
A | AGILENT TECHNOLOGIES INC | 23.31 | 36.01B | ||
IQV | IQVIA HOLDINGS INC | 16.43 | 32.03B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 30.93 | 26.06B | ||
WST | WEST PHARMACEUTICAL SERVICES | 36.65 | 18.34B | ||
WAT | WATERS CORP | 24.82 | 18.07B | ||
ILMN | ILLUMINA INC | 24.93 | 15.94B | ||
TEM | TEMPUS AI INC | N/A | 15.29B | ||
MEDP | MEDPACE HOLDINGS INC | 36.93 | 13.95B | ||
ICLR | ICON PLC | 13.33 | 13.71B | ||
RVTY | REVVITY INC | 17.8 | 10.10B |
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2017-12-07. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
QUANTERIX CORP
900 Middlesex Turnpike
Billerica MASSACHUSETTS 01821 US
CEO: E. Kevin Hrusovsky
Employees: 471
Phone: 16173019400
The current stock price of QTRX is 5.505 USD. The price decreased by -1.34% in the last trading session.
The exchange symbol of QUANTERIX CORP is QTRX and it is listed on the Nasdaq exchange.
QTRX stock is listed on the Nasdaq exchange.
9 analysts have analysed QTRX and the average price target is 6.38 USD. This implies a price increase of 15.8% is expected in the next year compared to the current price of 5.505. Check the QUANTERIX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QUANTERIX CORP (QTRX) has a market capitalization of 255.82M USD. This makes QTRX a Micro Cap stock.
QUANTERIX CORP (QTRX) currently has 471 employees.
QUANTERIX CORP (QTRX) has a support level at 5.25 and a resistance level at 6.34. Check the full technical report for a detailed analysis of QTRX support and resistance levels.
The Revenue of QUANTERIX CORP (QTRX) is expected to decline by -2.27% in the next year. Check the estimates tab for more information on the QTRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QTRX does not pay a dividend.
QUANTERIX CORP (QTRX) will report earnings on 2025-11-10, after the market close.
QUANTERIX CORP (QTRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
The outstanding short interest for QUANTERIX CORP (QTRX) is 9.68% of its float. Check the ownership tab for more information on the QTRX short interest.
ChartMill assigns a technical rating of 2 / 10 to QTRX. When comparing the yearly performance of all stocks, QTRX is a bad performer in the overall market: 94.94% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to QTRX. While QTRX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months QTRX reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS decreased by -43.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -18.77% | ||
ROE | -24.11% | ||
Debt/Equity | 0 |
9 analysts have analysed QTRX and the average price target is 6.38 USD. This implies a price increase of 15.8% is expected in the next year compared to the current price of 5.505.
For the next year, analysts expect an EPS growth of -121.83% and a revenue growth -2.27% for QTRX